NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

Home・Aktien・Roche Holding AG

Roche Holding AG

Geschlossen

BrancheGesundheitswesen

325.6 0.74

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

325.4

Max

326.6

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.8B 5.5B
Verkäufe	15B 31B
KGV Branchendurchschnitt	20.461 67.147
Dividendenrendite	2.97
Gewinnspanne	17.892
Angestellte	103,249
EBITDA	5.1B 12B

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	2.97% 2.36%

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-28B 261B
Vorheriger Eröffnungskurs	324.86
Vorheriger Schlusskurs	325.6

Nachrichtenstimmung

By Acuity

14%

86%

24 / 347 Ranking in Healthcare

Roche Holding AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Apr. 2026, 07:46 UTC

Ergebnisse

Roche Backs Full-Year View as Quarterly Sales Rise -- Update

23. Apr. 2026, 05:40 UTC

Ergebnisse

Roche Backs Full-Year View as Quarterly Sales Rise

9. März 2026, 16:43 UTC

Wichtige Markttreiber

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

9. März 2026, 15:44 UTC

Wichtige Markttreiber

Correction to Roche Shares Article

9. März 2026, 09:51 UTC

Wichtige Markttreiber

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

6. März 2026, 09:24 UTC

Wichtige Markttreiber

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

29. Jan. 2026, 10:07 UTC

Ergebnisse

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29. Jan. 2026, 07:07 UTC

Ergebnisse

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

27. Apr. 2026, 09:54 UTC

Market Talk

Roche's Vabysmo U.S. Recovery Will Be Key -- Market Talk

23. Apr. 2026, 08:10 UTC

Market Talk

Ergebnisse

Roche Reports In Line Sales Figures -- Market Talk

23. Apr. 2026, 05:04 UTC

Ergebnisse

Roche Backs 2026 View

23. Apr. 2026, 05:04 UTC

Ergebnisse

Roche Diagnostics Division 1Q Sales Up at 3% Constant Currency

23. Apr. 2026, 05:03 UTC

Ergebnisse

Roche Pharmaceutical Division 1Q Sales Up 7% at Constant Currency

23. Apr. 2026, 05:02 UTC

Ergebnisse

Roche 1Q Group Sales Up 6% at Constant Currency

23. Apr. 2026, 05:02 UTC

Ergebnisse

Analysts Saw Roche 1Q Sales at CHF14.73B

23. Apr. 2026, 05:01 UTC

Ergebnisse

Roche 1Q Sales CHF14.72B

10. Apr. 2026, 11:28 UTC

Market Talk

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

10. Apr. 2026, 11:17 UTC

Market Talk

Roche to Face Significant Currency Headwinds -- Market Talk

11. März 2026, 10:57 UTC

Market Talk

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

9. März 2026, 09:43 UTC

Heiße Aktien

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

6. März 2026, 07:22 UTC

Market Talk

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

3. März 2026, 07:22 UTC

Market Talk

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2. März 2026, 14:21 UTC

Market Talk

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

29. Jan. 2026, 11:40 UTC

Market Talk

Ergebnisse

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29. Jan. 2026, 06:05 UTC

Ergebnisse

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29. Jan. 2026, 06:04 UTC

Ergebnisse

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29. Jan. 2026, 06:03 UTC

Ergebnisse

Roche Issues 2026 View

29. Jan. 2026, 06:02 UTC

Ergebnisse

Analysts Saw 2025 Core EPS at CHF19.70

29. Jan. 2026, 06:02 UTC

Ergebnisse

Roche: 2025 Core EPS CHF19.46

29. Jan. 2026, 06:01 UTC

Ergebnisse

Analysts Had Seen 2025 Sales At CHF61.47B

Peer-Vergleich

Kursveränderung

Roche Holding AG Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Roche Holding AG – Dist abgegeben haben.

Stimmung

By Acuity

24 / 347 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.